glp 1 for liver GLP-1 Receptor Agonists in Non-Alcoholic Fatty Disease: Current Evidence and Future Perspectives Effects of GLP-1 receptor agonists
Description
doi: 10.3389/fendo.2024.1520313 Received 31 October 2024 Accepted 26 December 2024 Published 21 January 2025 Volume 15 - 2024 Edited by Joseph M
Runge et al
[1] These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)
The problem is that these Glucagon-like peptide-1 (GLP-1) drugs were initially approved to treat type 2 diabetes, and later received approval as weight-loss medications, researchers said
Subcutaneous injection means the needle enters the fatty tissue just below the skin
